Stock Ratings / Health Care / BRTX / insiders

PPCB (32) ELAB (27) REVB (36) BDRX (49) ⌘ Pro Terminal →

BioRestorative Therapies Inc. (NV) (BRTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is BRTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BRTX last traded at $1.40 (-11.37% on volume of 28,799 shares), positioning the stock -44.22% below its 50-day simple moving average ($2.51) and -77.74% below its 200-day simple moving average ($6.29). Across its 52-week range of $1.28 to $31.00, BRTX sits at the 0.4% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.23 to $1.57).

Q: Are BRTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BRTX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.40 -11.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.37

BioRestorative Therapies Inc. (NV) (BRTX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BRTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, BioRestorative Therapies Inc. (NV) (NASDAQ: BRTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.40 (-11.37% 1D, market cap $2.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BRTX ranks #448 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BRTX compare to PPCB and ELAB in the Health Care sector?

▼

Within the Health Care sector (Managed Health Care), BRTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 93.4%, and ROIC of -35.0%. By comparison, PPCB (Propanc Biopharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M) and ELAB (PMGC Holdings Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M). Among the 5-stock peer group, BRTX leads on earnings multiple (N/A) while BRTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BRTX?

▼

Per BRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001505497), BioRestorative Therapies Inc. (NV) generated $359.7K in revenue (-10.3% YoY), -$14.2M in net income, and -$10.9M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.37 (-2.24%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY BRTX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.9 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.91-19.4% Next Q

Q2 (-2Q)

Grade D$1.54+5.2% Next Q

Q3 (-1Q)

Grade D$1.62-13.6% Next Q

Current

Grade D$1.40-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BRTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BRTX currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.51) and Max Pain ($1.47) forces dealer call-delta covering toward $32.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BRTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BRTX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BRTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BRTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRTX)

✓Walkthrough of BRTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BRTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.89%▲ RESISTANCE BREAKOUT

2026-10-30O $1.58H $1.58L $1.40C $1.40VOL 28.7K

RES: $1.07SUP: $0.74SMA50: $2.51SMA200: $6.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BRTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BRTX Butterfly Map → + Track BRTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -10.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BRTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BRTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BRTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRTX)

Health Care Rank #448 of 1016 ⚔️ PPCB vs BRTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BRTX vs. PPCB, ELAB, REVB, BDRX)

Industry: Managed Health Care (1 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioRestorative Therapies Inc. (NV) (BRTX) ranks #448 by composite RQD confidence (44/100, grade D) and #993 by equity capitalization ($2.2M). Within this direct 5-issuer industry benchmark cohort, BRTX leads on earnings valuation at N/A trailing P/E, while BRTX leads on capital efficiency and profitability with -35.0% ROIC and 93.4% gross margin. BDRX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with BRTX at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BRTX ACTIVE BioRestorative Therapies Inc. (NV)	D	44/100	—	93.4%	-35.0%	-11.37%	$2.2M	Benchmark Subject
PPCB Propanc Biopharma Inc.	E	32/100	—	—	-35.0%	-12.80%	$2.2M	/ppcb-vs-brtx →
ELAB PMGC Holdings Inc.	E	27/100	—	31.4%	-35.0%	-1.51%	$2.1M	/elab-vs-brtx →
REVB Revelation Biosciences Inc.	D-	36/100	—	—	-35.0%	+7.47%	$2.1M	/revb-vs-brtx →
BDRX Biodexa Pharmaceuticals plc American Depositary Shs	D	49/100	—	—	—	-12.05%	$2.0M	/bdrx-vs-brtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001505497

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioRestorative Therapies Inc. (NV) (BRTX) reported GAAP revenue of $359.7K (-10.3% vs. FY2024 revenue of $401.0K , and +146.7% cumulative change since FY2023) , GAAP net income of -$14.2M, operating cash flow of -$10.8M, and free cash flow of -$10.9M (-30.8% YoY). On the balance sheet, BRTX closed FY2025 with $4.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$359.7K	-$14.2M	-$10.8M	-$10.9M	$4.1M	—
FY2024 (FY)	2024-12-31	$401.0K	-$9.0M	-$8.2M	-$8.3M	$12.3M	—
FY2023 (FY)	2023-12-31	$145.8K	-$10.4M	-$6.4M	-$6.4M	—	—

3. BRTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BRTX compare to PPCB and ELAB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BRTX?

Where is BRTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BRTX last traded at $1.40 (-11.37% on volume of 28,799 shares), positioning the stock -44.22% below its 50-day simple moving average ($2.51) and -77.74% below its 200-day simple moving average ($6.29). Across its 52-week range of $1.28 to $31.00, BRTX sits at the 0.4% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.23 to $1.57).

BRTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BRTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BRTX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: BRTX RQD Cockpit BRTX 12M Forecast BRTX Earnings & Move BRTX Dividends & DRIP BRTX Insiders & 13F BRTX Whale Options BRTX Profit Sankey BRTX News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BRTX — BioRestorative Therapies Inc. (NV): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:40Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BRTX scores 44 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 14/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Taken together, the weakest pillars are the cash engine and insider conviction, which are the two areas that most directly reflect whether the business generates value and whether those closest to it are committing capital. For a prospective investor evaluating the stock today, the rating signals that the fundamental cash profile and insider behavior do not currently support the thesis, and that the institutional flow pillar, while the strongest, does not offset the deficits. Upside drivers would need to come from a turnaround in cash generation, which the source data does not evidence. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. The rating itself is an analytical output and is not personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.4M	$-15.6M	$-14.2M	N/A	$-10.9M	$1.5M	N/A
FY 2024	$0.4M	$-11.6M	$-9.0M	N/A	$-8.3M	$0.5M	N/A
FY 2023	$0.1M	$-15.2M	$-10.4M	N/A	$-6.4M	N/A	N/A

Per the SEC financials, operating and net losses appear in every reported period, and the gross margin is listed at 93.4%, while operating and net margins are each -60%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5 with a Piotroski F-Score of 2/9. Debt-to-equity is 0.5 per the forensic pillar, though the debt line in the SEC financials is N/A for all periods, so the composition of that ratio is not available in source data. Cash is reported at $1.5M for FY 2025 versus $0.5M for FY 2024.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no supply chain is mapped (supply_chain: NONE), no butterfly links are recorded, and no proprietary signals are present. Sector context is limited to Health Care and Managed Health Care. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. Beta of 1.0 per the market data indicates market-level sensitivity, but sector correlation coefficients are not available in source data.

Open Questions

What is the composition of the debt figure behind the reported 0.5 debt-to-equity ratio, given that the SEC financials list debt as N/A for every period?
What are the FY 2025 EPS and share count, since EPS is N/A across all reported periods and EPS (TTM) is unavailable?
What drove the cash balance increase from $0.5M to $1.5M, and how is that funded relative to the FY 2025 FCF of $-10.9M?
What is the source of the institutional accumulation and options positioning referenced in the 13F pillar, given that holder data is NONE?
What catalysts, if any, are scheduled that could alter the cash trajectory, given that the news and catalyst section is NONE?

BRTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioRestorative Therapies Inc. (NV) (BRTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BRTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 61d ago

BioRestorative Therapies Announces Reverse Stock Split

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 130d ago

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 137d ago

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Com

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 160d ago

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILL

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 159d ago

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. (

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 179d ago

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety s

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 189d ago

Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing

Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Stre

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 171d ago

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates

Yahoo Finance coverage on BRTX stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BRTX Bull vs. Bear Conversation Board — What's Your Call at $1.40?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BRTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.23 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BRTX (D • RQD 44/100) a Buy at $1.40?

Welcome to the BRTX (BioRestorative Therapies Inc. (NV)) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Managed Health Care. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.05 (-25.0%)

Spot @ $1.40

Pump the brakes on BRTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BRTX, but look at what you are paying: current EV/EBITDA multiples with 93.4% gross margins. Unless BioRestorative Therapies Inc. (NV) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.72 (+22.9%)

Spot @ $1.40

BRTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BRTX, the market is fixating on short-term headline noise in Managed Health Care and ignoring the balance sheet and cash flow trajectory. At $1.40 (52-wk range $1.28 - $31.00), any beat on forward guidance forces shorts and underweight funds to chase.